

## Release notes for Fertilome® v1.5

As part of our on-going commitment to deliver the highest quality products, we routinely make updates and improvements to the Fertilome® genetic test. This is of critical importance as new clinical evidence emerges daily from ongoing research conducted by Celmatix and other investigators around the world. New and improved methods for collecting genetic samples and for detecting sequence variations also become available over time. Leveraging these updated technologies allows us to offer more convenience and better results to patients and physicians. These updates are approved by the relevant regulatory agencies and conducted under their oversight.

In the most recent update to the test:

- Our sequencing assay chemistry has been further optimized to allow for greater sequencing coverage. As a result, we are now able to detect new variants that were not previously reported in Fertilome v1.0.
- We have also validated the panel on DNA purified from saliva samples. This means that physicians can now send blood or saliva samples based on which method is the most convenient.
- Fertilome v1.5 reports also reflect the findings of our updated statistic validation and meta-analysis. During this process, we conducted a full audit and reproducibility study of the analysis upstream of v1.0. As part of this analysis, we also identified variants within the same gene that are in linkage disequilibrium and edited the reported variants accordingly. For more information on the new variants that have been added in this release or the ones that have been removed, please contact a member of our Genetic Communications Team.